Are you increasing the dose and/or frequency of Xolair administration if patients have failed standard dosing for CSU?

The data with omalizumab is clear that updosing is safe and effective. Dupilumab, omalizumab, and remibrutinib are all about equally effective (about 60%), but updosing omalizumab to 300 every 2 weeks and even to 600 every 2 weeks gives a 60% benefit to the 40% that fail 300 a month.